Login to Your Account



Tysabri Safety Data Good, But Skepticism Dies Hard

By Randall Osborne


Wednesday, August 10, 2005
Having found no new cases of progressive multifocal leukoencephalopathy in a completed safety review of Tysabri patients, Biogen Idec Inc. and Elan Corp. plc said they hope to get the multiple sclerosis drug back on the market, with regulatory paperwork to be filed in the fall. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription